Balance Sheets for Editas Medicine, Inc. (EDIT)

Add EDIT to watchlist(s)

You Should Create a Watchlist In The First Place.

Price Over Time

Profile

Company Name

Editas Medicine, Inc.

Symbol

EDIT

Currency

USD

Exchange

Nasdaq

Head Quarter

United States, Cambridge

Sector

Healthcare

Industry

Biotechnology

Website

https://www.editasmedicine.com

ISIN

US28106W1036

CIK

1650664

CUSIP

28106W103

UEI

-

LEI

-

Business Description

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss;